Research Reports | Market Assessment
September 2021

Market Events and Forecast | Oncology | US/EU5 | 2021

In 2019, sales of branded MAb biologics in oncology exceeded $20 billion in the major pharmaceutical markets (United States, EU5, and Japan), and the sales of biosimilars in these regions totaled $880 million. Throughout the 2019-2029 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports